Brief: Novo Nordisk Q3 Adjusted EBIT At DKK 31,720 Million, Above Estimates

Novo Nordisk A/S

04/11/2026 06:50

Novo Nordisk A/S NOVOb.CO:
Q3 ADJUSTED REVENUE DKK 79,195 MILLION
Q3 ADJUSTED EBIT DKK 31,720 MILLION
OUTLOOK FY ADJUSTED EBIT GROWTH -2 TO 2%
OUTLOOK FY ADJUSTED REVENUE GROWTH -2 TO 2%
ADJUSTED SALES GROWTH FOR 2026 IS NOW EXPECTED TO BE -2% TO +2% AT CER
Q3 ADJUSTED NET SALES DKK 79,195 MILLION VERSUS ESTIMATE DKK 73,217 MILLION
Q3 WEGOVY SALES DKK 20,407 MILLION VERSUS ESTIMATE DKK 19,936 MILLION
SEES 2026 ADJUSTED EBIT GROWTH OF -2% TO +2% AT CER AT CER (EARLIER VIEW: 0% TO -6%)
Q3 ADJUSTED EBIT DKK 31,720 MILLION VERSUS ESTIMATE DKK 28,394 MILLION
Q3 WEGOVY PILL SALES DKK 5,394 MILLION VERSUS ESTIMATE DKK 4,615 MILLION
IMPROVED OUTLOOK IS DRIVEN BY INCREASED EXPECTATIONS FOR GLP-1 PRODUCT SALES 
GROWTH WAS LED BY OUR OBESITY PORTFOLIO, WITH CONTINUED UPTAKE OF WEGOVY® PILL IN US AND ENCOURAGING EARLY LAUNCHES INTERNATIONALLY
PREPARING FOR US LAUNCH OF CAGRISEMA IN EARLY 2027, SUBJECT TO REGULATORY APPROVAL
BY END OF Q3, WEGOVY PILL HAD BEEN LAUNCHED IN US, UAE, UK AND GERMANY
SEES 2026 CAPEX OF AROUND 50 BDKK
Q3 ADJUSTED SALES DRIVEN BY GLP-1 VOLUME GROWTH IN BOTH OPERATING UNITS, PARTLY OFFSET BY LOWER REALISED PRICES
FY OUTLOOK ASSUMES, AMONG OTHERS, LOWER REALISED PRICES IN US OPERATIONS
SEES 2026 FREE CASH FLOW OF BETWEEN 60 AND 70 BDKK VERSUS BETWEEN 45 AND 55 BILLION SEEN EARLIER

Further company coverage: NOVOb.CO